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Background. The evolution of the variant Creutzfeldt-Jakob disease (vCJD) epidemic is hazardous to predict due to
uncertainty in ascertaining the prevalence of infection and because the disease might remain asymptomatic or produce an
alternate, sporadic-like phenotype. Methodology/Principal Findings. Transgenic mice were produced that overexpress
human prion protein with methionine at codon 129, the only allele found so far in vCJD-affected patients. These mice were
infected with prions derived from variant and sporadic CJD (sCJD) cases by intracerebral or intraperitoneal route, and
transmission efficiency and strain phenotype were analyzed in brain and spleen. We showed that i) the main features of vCJD
infection in humans, including a prominent involvement of the lymphoid tissues compared to that in sCJD infection were
faithfully reproduced in such mice; ii) transmission of vCJD agent by intracerebral route could lead to the propagation of either
vCJD or sCJD-like prion in the brain, whereas vCJD prion was invariably propagated in the spleen, iii) after peripheral exposure,
inefficient neuroinvasion was observed, resulting in an asymptomatic infection with life-long persistence of vCJD prion in the
spleen at stable and elevated levels. Conclusion/Significance. Our findings emphasize the possibility that human-to-human
transmission of vCJD might produce alternative neuropathogical phenotypes and that lymphoid tissue examination of CJD
cases classified as sporadic might reveal an infection by vCJD-type prions. They also provide evidence for the strong propensity
of this agent to establish long-lasting, subclinical vCJD infection of lymphoreticular tissues, thus amplifying the risk for
iatrogenic transmission.
Citation: Be ´ringue V, Le Dur A, Tixador P, Reine F, Lepourry L, et al (2008) Prominent and Persistent Extraneural Infection in Human PrP Transgenic
Mice Infected with Variant CJD. PLoS ONE 3(1): e1419. doi:10.1371/journal.pone.0001419
INTRODUCTION
The variant form of CJD (vCJD), thought to have arisen from
exposureofthepopulationtocattleBSE-contaminatedfood[1,2],is
perceived as the most threatening to public health among the
human prion diseases [3]. Nearly two hundred patients have died
from vCJD worldwide currently (http://www.cjd.ed.ac.uk/
vcjdworld.htm), all of which were homozygous for methionine (M)
at the polymorphic Prnp codon-129, a genotype harbored by ,40
percent of the population. The disease incidence has declined since
2000 in the UK, and recent predictions suggest that the epidemic
will remain relatively limited in size [4]. However, major
uncertainties such as the actual spread of the infectious agent
within the population, the proportion of infected individuals who
are asymptomatic carriers, and the susceptibility of individuals with
non-MM genotypes, render difficult the projections of the future
course of vCJD [5]. A retrospective study that aimed to detect
abnormal PrP in tonsil and appendix specimens suggested a
considerably greater prevalence of vCJD infection than the
observed incidence [6,7]. The pronounced, preclinical involvement
of the lymphoid tissues, which appears to be a hallmark of vCJD
compared to sporadic CJD (sCJD) infection, conceivably enhances
the risk of human-to-human transmission [8–11]. Also, BSE/vCJD
transmission studies in macaques suggested an increased virulence
of the host-adapted agent [12], as generally observed when prions
cross a species barrier. For all these reasonsand the recent reporting
of four vCJD cases associated to blood transfusion [13–15], the
extend of the iatrogenic risk associated with subclinical vCJD
infection needs to be assessed more precisely.
Mice genetically engineered to express human PrP on a
nullizygous mouse PrP background have provided new animal
models in which to propagate and study the properties of BSE/
vCJD agent. Mice that express the PrP allele with M (tg35 and
tg45 lines) or V (valine; tg152 line) at codon-129 at supra-
physiological levels, while exhibiting a greatly enhanced suscep-
tibility to sCJD compared to wild-type mice, produced a complex
pattern of transmission upon BSE or vCJD challenge. Thus, BSE
prions were reported to propagate as vCJD-like or sCJD-like prion
strains in tg35 mice, while propagation of vCJD in tg152 mice led
to the appearance of a distinct strain phenotype [16,17]. Such
findings, together with those from recent molecular strain typing
studies [18], raised the concern that propagation of BSE-derived
prions in human might result in novel phenotypes. The effect of
codon-129 on the susceptibility to human-to-human vCJD
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in which the mouse PrP gene was replaced by human PrP genes
with the MM, VV and MV genotypes [19]. While BSE failed to
transmit, vCJD transmitted infection to all three lines though with
variable efficiency, strengthening the concern of an iatrogenic risk
irrespective of genotype. Despite their potential relevance, such
mouse models have remained largely unexploited with respect to
the peripheral pathogenesis of BSE/vCJD infection. Indeed, apart
from a recent report describing the detection of abnormal PrP in
splenic follicular cells of knock-in mice expressing a mouse/human
PrP chimera within months after vCJD infection [20], there are no
published data regarding the fate of infection after peripheral
challenge, or the propagation of prions in extraneural tissues.
In the present study we analyzed the transmission characteristics
of vCJD in ‘humanized’ mice, shown to be fully susceptible to the
disease. We report the unexpected finding that vCJD prions
derived from a natural human isolate can induce the propagation
of two distinct prions strains in the brain of mice expressing a
homologous PrP protein. We also show that infection in these mice
closely parallels vCJD infection in humans with enhanced tropism
for lymphoreticular tissues compared to sCJD agent, thus
providing a potentially relevant model to investigate the peripheral
propagation of vCJD at different stages of the incubation.
RESULTS
Efficient disease transmission following
intracerebral inoculation of vCJD to tg650 mice
tg650 is a newly developed transgenic line that overexpresses
human PrP
C M
129 allele at a 6-fold level on a PrP null background
(see Text S1; Figure S1). To evaluate its susceptibility to vCJD,
mice were inoculated intracranially with human infected brain
tissue from 3 French cases, and 1 UK case (WHO reference). The
resulting transmission data are summarized in table 1, together
with those from sCJD cases assayed for comparison. Remarkably,
all vCJD inocula induced a clinical neurological disease, with a
100% attack rate. The observed survival times typically averaged
500 days in homozygous mice, and were relatively homogenous
overall. Intriguingly however, a proportion of mice inoculated with
the case no. 4 developed the disease at a much earlier time (,300
days) than the others. Such a distribution into two groups (termed
early and late thereafter) was consistently found in homozygous
mice, challenged with 2 distinct aliquots of the same material, as
well as in hemizygous mice, initially used during the course of the
study. Altogether 7 out of the 16 mice infected with vCJD no. 4
developed an early disease (Table 1).
To clarify the situation observed in vCJD no. 4-challenged
mice, late and early brain materials from individual mice (sacrificed
at 586 and 302 days, respectively) were subjected to a secondary
transmission (see Table 1). Late brain-inoculated mice died at
,500 days, a survival time that neither changed on 3
rd passage
(497618; 10/10 mice) nor differed significantly from that seen
upon primary transmission of vCJD on homozygous mice
(Table 1). A much shorter incubation period (,160 days), similar
to that with secondary passed sCJD was observed upon early brain
passage (Table 1), suggesting that distinct prions had propagated
in early and late mice.
PrP
res in early succumbing tg650 mice is sCJD-type
in the brain but vCJD-type in the spleen
The nervous and lymphoid tissues were examined for the presence
of proteinase K (PK)-resistant PrP (PrP
res) by immunoblotting.
PrP
res was readily detected in the brains of all the vCJD- and
sCJD-infected mice analyzed. A typical PrP
vCJD banding pattern,
Table 1. Transmission of variant and sporadic CJD cases to tg650 mice expressing human PrP.
..................................................................................................................................................
Inoculum Number (Origin)
Mean6SEM survival time in days (n/n0)
1 PrP
res pattern
1
st passage 2
nd passage Brain Spleen
Variant CJD 1 (Fr) 522618 (5/7)
2 na vCJD vCJD
[129 MM] 2 (Fr) 512615 (8/8) 520626 (7/7) vCJD vCJD
3 (Fr) 515641 (8/8) na vCJD vCJD
4 (UK)
3 506621 (6/10)
4 na vCJD vCJD
338642 (5/10)
4 na sCJD vCJD
4 (UK)
5 628615 (4/7)
6 491637 (7/7) vCJD vCJD
302; 342 (2/7) 15462 (6/6) sCJD vCJD
7
Sporadic CJD 1 (UK)
4 17761 (8/8) 15363 (4/4) sCJD neg
8
[129 MM] 1 (UK) 15363 (4/4) 15762 (6/6) sCJD neg
2 (Fr) 15963 (6/6) 16162 (6/6) sCJD neg
3 (Fr) 16263 (6/6) na sCJD neg
4 (Fr) 16762 (6/6) na sCJD neg
Human brain
9 (Fr) 764635 (0/9) neg neg
na, not available; Fr, French; UK, United Kingdom
1Intracerebral inoculation with 2 mg brain tissue equivalent; n/n0: diseased, PrP
res positive/inoculated animals.
2Two tg650 mice died of intercurrent disease at 166 and 274 days but were PrP
vCJD positive in both brain and spleen.
3Done in two independent experiments (different schedule and homogenate batch), of which the results are pooled for the sake of clarity.
4One tg650 mouse that succumbed with disease at 437 days had a mixed PrP
res profile (Figure S4) and was included for calculation of both survival times.
51
st passage performed on hemizygous mice.
6One tg650 mouse died of intercurrent disease at 411 days, but was PrP
vCJD positive both in brain and spleen.
7All mice and half of the mice accumulated vCJD-like PrP
res in their spleen on 1
st and 2
nd passage, respectively. The others were negative.
8neg: negative.
9Patient with no TSE disease.
doi:10.1371/journal.pone.0001419.t001
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PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1419characterized by low size fragments and prominent diglycoform
species, was observed in vCJD no. 1 to 3-challenged mice and in
vCJD no. 4 late mice (23/23 and 9/9 mouse brains analyzed,
respectively, Figure 1A–B), a signature that was maintained in the
brain of secondary inoculated mice (6/6 analyzed; Figure 1B, D).
vCJD no. 4 early mice, however, showed a clearly distinct PrP
res
profile withpredominantly monoglycosylated, higher size fragments
(6/6; Figure 1A–C). Such a signature, termed PrP
sCJD because of its
similarity with that in sCJD-challenged mice was conserved on
subsequent passage (35/35 analyzed; Figure 1A, B, D).
While no PrP
res accumulation was evident in the spleens of
sCJD-infected mice (12/12 analyzed), PrP
res was consistently
detected in the spleens from vCJD-infected mice (32/32)
(Figure 1A; Table 1). Remarkably, early and late mice showed a
similar PrP
res signature, unlike that in the corresponding brains
(Figure 1A–C). The observed banding pattern was typical of
PrP
vCJD, despite of a slightly modified glycoform ratio compared
to that in the brain, as already noted in human infected patients
[10]. PrP
vCJD was also detected in the spleens of half of the mice
(2/4) inoculated with early mouse brain (Table 1 and Figure 1D),
thus suggesting that vCJD type agent was replicated as a minor
component in the brains of a number of early mice and then
preferentially amplified in the spleen on subpassage.
vCJD propagated as sporadic- or variant-like CJD
strain in the brain of tg650 mice
To confirm that the biological and molecular disparities observed
after transmission of vCJD no. 4 reflected the propagation of two
distinct prion strains, we examined the regional distribution of
abnormal PrP and spongiform lesions in the brain, which are
known to exhibit strain-dependant variations. We first performed
histoblots analyses on antero-posterior coronal frozen sections to
compare the distribution of PrP
res in the brains of mice inoculated
with late or early brain. In late brain passage, abundant and large,
plaque-like PrP deposits were scattered throughout the brain,
Figure 1. Western blots analysis of PrP
res in the brains and spleens of tg650 mice infected with sporadic and variant CJD by intracerebral route.
(A) Electrophoretic pattern of PrP
res in the brain (upper panel) and spleen (lower panel) upon primary transmission. Note that vCJD case no. 4 shows
either a typical vCJD or sCJD-like pattern in the brains of mice succumbing late or early with disease, respectively, while a vCJD-like pattern is
consistently observed in the spleens. The PrP
res profiles of variant and sporadic CJD in the brain of affected human patients are shown on the sides
(left and right, respectively) of both immunoblots for comparison. (B) Ratio of diglycosylated and monoglycosylated PrP
res species in the brains of
mice following serial transmission of sporadic or variant CJD cases (data plotted as means6SEM). PrP
vCJD and PrP
sCJD patterns are represented by
brown and grey colors, respectively. Variant CJD cases no. 1, 2, 3 and 4 are represented as diamond, circle, square, and triangle; sCJD cases no. 1, 2, 3
and 4 as polygon, star, ellipse, and rectangle. Secondary transmissions (when available) are represented by the same, unfilled symbols. Note the
distinct glycoform ratio between early (grey triangle) and late brains upon transmission of vCJD case no. 4. (C) In early succumbing mice, the size of
the PrP
res fragments is higher in the brain (Br) than in the spleen (Sp), whereas in late succumbing it remains similar, as shown after deglycosylation
by PNGase treatment. MM: molecular markers. (D) Electrophoretic pattern of PrP
res in the brain and spleen upon secondary transmission. tg650 mice
were inoculated with brain or spleen homogenates from either sCJD or vCJD case 4 late or early mice. The brain PrP
res profile of human vCJD is shown
on the left side of the gel for comparison.
doi:10.1371/journal.pone.0001419.g001
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PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1419predominantly in the cerebral cortex, corpus callosum, several
nuclei of the thalamus, optic tract and brain stem, a distribution
similar to that seen in vCJD 1–3 brains (Figure 2; Table S1). In
sharp contrast, PrP deposition in early brain passage was absent in
most of these regions (Figure 2; Table S1). The staining was much
less intense, rather diffuse, but nevertheless specific as compared to
mock-infected mice (Figure 2). It was restricted to the ventral
pallidum, dorsolateral geniculate, lateral posterior and mediodor-
sal nuclei of the thalamus and external cortex of the inferior
colliculus, resembling that in sCJD 1–3 brains (Figure 2; Table S1).
The distinct nature of abnormal PrP deposits was further
assessed by light and fluorescent microscopy examination of fixed
and frozen sections. Numerous plaques were present only in late
brain passage (Figure S2). Their structure had a typical aspect
arranged in peripheral radiating spicules (Figures 3A and S3).
They were Congo red (Figure 3A) and thioflavin-S positive (Figure
S3), indicating an amyloid fibrils organization. A large number of
these dense deposits were surrounded by a ring of vacuoles
(Figure 3A), a morphology typical of the florid plaques observed in
vCJD-infected humans [1]. Examination of histopathologic lesions
in several areas of the brain indicated that spongiosis was
prominent in the thalamus of late brain passage, whereas striatum
and cortex were mostly damaged in early brain passage (Figure 3B).
Astrogliosis activation was important in the thalamus and cortex
frequently at the vicinity of the plaques in late brain, whereas it was
spatially unrelated to PrP
res deposition in early mice (Figure S2). In
one of the early brains, the observed PrP distribution suggested the
presence of both PrP
sCJD and PrP
vCJD, consistent with the mixed
PrP
res electrophoretic pattern visible on the immunoblot (Figure
S4).
Long-lasting persistence of vCJD prion in the spleen
following peripheral inoculation
We next sought to investigate the pathogenesis of the infection
following inoculation of tg650 mice by the peripheral route. Mice
were inoculated intraperitoneally with brain material from vCJD-
or sCJD-infected humans and from vCJD no. 4 mouse passages.
Animals were euthanised at various times post-infection (pi), from
which the brain and spleen were collected for PrP
res analysis by
immunoblotting. Importantly, mice inoculated with vCJD prions
peripherally appeared not to develop clinical disease, unlike their
intracranially inoculated counterparts. Yet PrP
vCJD was readily
detected in the spleen, and this from 100 days pi onward
(Figure 4A). Moreover, quantitative analysis revealed that the
PrP
res levels did not greatly vary during the life of the mouse
(Figure 4B–C), except perhaps a slight decrease at late stage of
infection, possibly due to age-related impairment of the follicular
dendritic cells (for review [21]) that support PrP
res accumulation in
spleen [22]. In the brain, PrP
res was detected only lately and in a
proportion of the mice; its banding pattern was of vCJD type in late
mice and of sCJD type in early mice subpassage, like following
Figure 2. Regional distribution of PrP
res in the brains of tg650 mice infected with vCJD and sCJD. The distribution of PrP
res deposits in the brains
of tg650 mice infected with vCJD no. 4 late or early brain, vCJD (case no. 1), and sCJD (case no. 2) or non-TSE material (mock) is shown on
representative histoblots in 4 different antero-posterior sections. Note the differing size and distribution of PrP
res deposits between late and early
brain, and their similarity to that observed with vCJD and sCJD, respectively.
doi:10.1371/journal.pone.0001419.g002
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intraperitoneal challenge, we failed to detect PrP
res accumulation
in the spleens of sCJD-infected mice (Figure 4C).
In order to evaluate the level of prion infectivity present in this
compartment, spleen homogenates of mice challenged intracere-
brally with either sCJD or vCJD cases were subpassaged
intracranially to recipient tg650 mice (at 10% w/v). The mice
challenged with sCJD spleens died at ,300 days (case no. 1:
29668 days, 5/6 mice infected; case no. 4: 33466 days, 6/6),
corresponding to infectivity levels ,10
4-fold lower than in the
brain by applying these values to a dose/survival curve drawn after
an endpoint titration (Figure S5). These low levels were consistent
with the lack of detectable PrP
res (Figures 1 and 4) In sharp
contrast, the mice challenged with vCJD spleen died at 500661
days (6/6), a survival time intermediate between that observed
after inoculation of vCJD brain at the 10% and 1% doses
(497618; (10/10 mice) and 537613 days; (7/7), respectively). The
PrP
res profiles in the brains and spleens of the reporter mice were
consistent with the replication of sCJD and vCJD agents,
respectively (Figure 1D). Thus vCJD infectivity levels in the spleen
and brain of tg650 mice are unlikely to differ by more than about 1
order of magnitude. Such an estimate is consistent with the PrP
res
level ratios in spleen versus brain homogenates (between 5 to 20-
fold less). It is notable that this PrP
res ratio is close from that
reported in humans [10]. Moreover, inoculation of vCJD-infected
human spleen tissue killed tg650 mice within 570663 days (5/5),
which indicates an infectivity level approaching that in tg650
mouse spleen. In contrast, infectivity levels 100- to 1000-fold lower
than in the brain were reported for vCJD-infected human spleen
tissue through titration in RIII mice [23].
DISCUSSION
In this study we used tg650 mice, a newly developed transgenic
line expressing human PrP
C, to investigate some aspects of the
pathogenesis of vCJD infection. As main findings, we demonstrate
that prion strain divergence can occur upon transmission of
human, primary vCJD to such mice, and that peripheral challenge
leads to an asymptomatic, life-long infection of the lymphoid
compartment. A feature of tg650 mice is that following primary
intracerebral vCJD challenge they developed a neurological
disease with typically 100% attack rate, unlike for previously
established PrP
129Met, including overexpressing lines [16,19]. The
mean survival time – typically around 500 days in homozygous
mice - did not change notably on subpassaging, implying that
vCJD agent might clinically infect the tg650 mice with little or no
transmission barrier. This discrepant result may reflect the use of
different constructs and genetic backgrounds (Text S1), and the
transgene expression levels, although the latter does not seem to
greatly differ as far as the tg650
+/2 and tg45 mice [16] are
concerned.
A surprising result of these studies is the alternate pattern of
disease that was induced by one of the inoculated vCJD cases, a
WHO reference case here designated vCJD no. 4. Indeed, while
vCJD strain features were faithfully propagated in the majority of
tg650 mice, almost half of the vCJD 4-inoculated mice were found
to propagate a prion replicating faster than vCJD agent, and
exhibiting sCJD-like PrP
res and neuropathological features.
Although strain divergence upon transmission of BSE/vCJD
agent to mice was reported to occur in earlier studies [16,24], it
was unprecedented within a context of homotypic transmission,
i.e. full matching between the donor and receiver PrP sequences.
To address the issue of a possible contamination, we performed
independent transmission experiments, involving separate inocu-
lum batches of the incriminated case, which all produced
consistent results. Therefore, we consider the data inconsistent
with contamination of the VCJD no. 4 material by a sCJD
infectious source within our laboratory. An alternate possibility,
Figure 3. PrP
res plaques and spongiform changes in mice infected
with vCJD no. 4 late or early brain. (A) PrP plaques were visible, here in
the cortex of late brain passage, after periodic acid-Schiff (PAS) and
Congo red staining. Note that their morphology and the surrounding
ring of vacuoles are typical of florid plaques, a pathological hallmark of
vCJD in human. (B) Hematoxylin and eosin staining of brain sections
from mice infected with late or early brain. Note the distinct
regionalization of vacuolation among the two agents. Th; thalamus.
Bars: (A)=200 mm. (B)=100 mm.
doi:10.1371/journal.pone.0001419.g003
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res accumulation in tg650 mice intraperitoneally infected with vCJD. (A) PrP
res electrophoretic pattern in spleen (sp, circle) and brain
(br, square) of mice euthanised healthy in triplicates up to 550 days post-infection (broken line) or at end of life time. vCJD- and sCJD-associated PrP
res
pattern are represented as brown and grey color, respectively. Empty symbols indicate PrP
res negative tissue. Mock-infected mice (mock) were
intraperitoneally inoculated with human brain without any TSE. (B) Quantification of PrP
res levels in the spleens on secondary transmission of vCJD
(late brain). Spleen tissue was collected from healthy mice euthanised in triplicates at regular time points or individually at the end of life (see above).
PrP
res was extracted, detected by western blot and quantified with a bio-imaging system for chemiluminescence applications (see Methods). Results
are expressed in arbitrary units (logarithmic scale). The standard deviations for triplicates without error bars were too small to be represented. (C)
Electrophoretic pattern of PrP
res in brain (Br) spleen (Sp) at various times after inoculation of the indicated brain materials.
doi:10.1371/journal.pone.0001419.g004
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highly improbable owing to the procedures applied during the
collect of the specimen and the preparation of the homogenates
([25] and P. Minor, personal communication). On the other hand,
our observation intriguingly parallels the phenotypic disjunction
observed upon transmission of BSE agent to human PrP
129Met
mice (tg35 line [16]). Together, these findings lend support to the
hypothesis that a minor strain component might be created upon
cattle-to-human transmission of BSE agent and could emerge
upon subsequent human-to–human transmission. It is also worth
mentioning that, while the probability to detect such a variant
through mouse bioassay would be expected to depend on the
amount - and possibly the regions - of brain tissue taken to
establish the source material, the vCJD-4 homogenate was
prepared using a larger amount of tissue from the same brain
than for the other homogenates analyzed in this study (i.e. 100 mg
instead of 1 mg of frontal cortex [25]).
The above finding has obvious implications in terms of public
health as it raises the concern that some humans iatrogenically
infected by vCJD agent may develop a clinical disease that would
not be recognized as of vCJD origin [17,26]. Strikingly however, all
vCJD-4-inoculated mice, notwithstanding the strain phenotype
divergencepropagatedbonafidevCJDagentintheirspleen,basedon
thePrP
respatternand the diseasephenotypeproducedbysecondary
transmission to tg650 mice. This result is of direct relevance to the
diagnosis of variant and sporadic CJD. Indeed, looking for
peripheral lymphoreticular deposition of abnormal PrP on cases
diagnosed as sporadic CJD might reveal a vCJD infection resulting
from human-to-human, or cattle-to-human transmission. In this
respect, it would be of interest to examine whether BSE-inoculated
tg35 mice showing discordant PrP
res signatures [16], or vCJD-
challenged PrP
129Val transgenic mice producing ‘type 5’ prion in
their brain [17] do accumulate PrP
vCJD in their spleens. In any case,
our findings provide clear evidence that, as a consequence of strain-
related tropism disparities, the same mouse can propagate different
prions in different tissues following a single infection event.
Another salient finding emerging from this study was the
remarkable ability of vCJD agent to establish asymptomatic
infection despite sustained, life-long propagation in extraneural
tissues. When challenged peripherally, tg650 mice remained
asymptomatic over the whole observation period, and did not
accumulate PrP
res at detectable levels in their brain before 750
days pi, near the life end-stage. In the spleen of these mice
however, PrP
res accumulation reached its maximum at an early
stage of infection, and remained at stable and substantial levels
until death. Plateauing of prion infection in the spleen is consistent
with earlier observations, and has been suggested to reflect an
exhaustion of target cells (for review [22]) Importantly, the spleen
tissue was highly infectious as it killed 100% of intracerebrally
challenged mice within the minimal mean incubation time (,500
days). Altogether these data support the view that the sustained
multiplication of the vCJD prion in lymphoid tissues was not
accompanied by an efficient neuroinvasion in tg650 mice. Such an
extremely delayed neuroinvasion appears to be rare in TSE rodent
models, and to our knowledge was only reported for the mouse-
adapted strain 87V on IM mice infected intraperitoneally with
diluted inoculum [27]. Clearly, while early accumulation of prions
in lymphoid tissues may be essential for efficient neuroinvasion
[22], efficient lymphoinvasion does not inevitably lead to rapid
neuroinvasion. This finding strengthens the notion that humans
infected by vCJD from a human source – including individuals of
the MM genotype – might remain clinically asymptomatic for a
very prolonged period of time while harboring relatively high
levels of prion infectivity in their lymphoid tissues from an early
stage of infection on, thereby amplifying the risk of iatrogenic
transmission. It also supports the view that the large-scale survey of
lymphoreticular tissues [28] may lead to a reliable assessment of
the actual prevalence of vCJD infection in the UK population.
Finally, the human PrP transgenic model described in this study
may help to further our understanding of peripheral vCJD
pathogenesis, for instance in trying to identify factors that might
enhance neuroinvasion efficiency, or modulate the shedding of
prion infectivity from the lymphoreticular to the blood compart-
ment. Moreover, preliminary results indicate that the search for
abnormal PrP in the spleen of such mice culled at time intervals
post infection [29,30] could allow the detection of low levels of
vCJD infectivity within a reasonably short time scale.
METHODS
CJD samples
Two WHO reference brain samples sCJD no. 1 (code NHBY0/
0001) and vCJD no. 4 (code NHBY0/0003) [25] and a vCJD-
patient spleen (code NHSY0/0009) were provided by the National
Institute for Biological Standards and Control (NIBSC; Potters
Bar, United Kingdom). The other samples were collected in
French hospitals. All samples consisted of frontal cortex from
patients homozygous for methionine at PrP codon-129. Consent
for use of these materials for research was obtained.
Mouse transmission assays
Details of how the tg650 transgenic mouse line was created are
supplied as supplementary information (Text S1). Animal
experiments have been performed according to our institutional
and national guidelines. Rigorous protocols were followed
throughout the study to avoid any cross-contamination in the
laboratory. Each inoculum was prepared extemporaneously in a
class II microbiological cabinet using disposable equipment. 20 ml
of a 10% or 100 ml of a 2% (wt/vol) brain homogenate in 5%
glucose were inoculated in individually identified 6- to 10-week old
mice by intracerebral or intraperitoneal route, respectively, using
disposable syringes. Mice were sequentially euthanised to study the
kinetics of PrP
res accumulation in brain and spleen after
intraperitoneal injection. Otherwise mice were monitored daily
and those showing disease signs or at end of lifespan were
euthanised in extremis. Separate instruments were used for brain
and spleen tissues. Instruments were decontaminated with 1M
sodium hydroxide for 24 h followed by double autoclaving at
136uC before re-use. All collected tissues were identified
individually by a database code with highly resistant thermal
labels designed for long-term storage (Brady Corp).
PrP
res immunoblots
All procedures regarding extraction and detection of PrP
res from
brains and spleens of infected mice have been previously described
[31,32]. The ICSM18 [33] or Sha31 [34] anti-PrP antibodies were
used. Enzymatic deglycosylation was performed on denatured
PrP
res with 1,000 U of recombinant PNGase (New England
Biolabs) for 2 h at 37uC in 1% Nonidet P40 and the proprietary
buffer as described [33]. Glycoform ratios, apparent molecular
mass and quantification of PrP
res signals were determined by the
GeneTools software after acquisition of chemiluminescent signals
with a GeneGnome digital imager (Syngene).
Histoblots
Brains were rapidly removed from euthanised mice and frozen on
dry ice. Thick 8–10 mm cryostat sections were cut, transferred
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analyses were performed on 3 brains per infection, using the 3F4
anti-PrP antibody as described [31].
Immunofluorescence
Cryostat sections were formalin-fixed before permeabilisation with
0.5% Triton X-100 for an hour. Abnormal PrP epitopes were
exposed with 3M guanidine-HCl for 5 min [35]. Endogenous
avidin and biotin were blocked using a specific kit (Zymed). PrP
res
was detected with ,2 mg/ml biotinylated 3F4. Astrocyte activa-
tion was visualized by labeling with anti-glial fibrillary acidic
protein (GFAP, Dako). Sections were incubated with appropriate
Alexa-conjugated streptavidin or secondary antibodies (Molecular
probes) and nuclear marker 49, 6-diamidino-2-phenylindole
(Sigma) before mounting in fluoromount (Sigma). Age-matched
uninfected tg650 mice were similarly stained as controls. Signals
were acquired with an inverted fluorescence microscope (Zeiss
Axiovert) and analyzed with the Metamorph software.
Histopathology
Brains were removed from euthanised mice and the 2/3 were
fixed in 4% phosphate buffered formalin. Seven-micrometer–thick
sections from paraffin embedded samples were stained with
hematoxylin and eosin, periodic acid-Schiff and Congo red [36].
Thioflavin-S staining (Sigma) was performed as previously
described [37,38] with slight modifications of method. Briefly,
after a pre-treatment by immersion in 0.1% KMnO4 in PBS for
20 min followed by 1% oxalic acid in PBS for 3 min and 1%
H2O2 and NaOH in PBS for 5 min, sections were stained using a
0.01% solution of Thioflavin-S in 40% EtOH. Finally sections
were differentiated in 50% EtOH in PBS, rinsed in PBS,
coversplipped and observed using a Zeiss Axiovert 200M
microscope equipped with a Coolsnap HQ CDD camera and
using Metaview software.
SUPPORTING INFORMATION
Figure S1 Relative PrPC levels in the brain and spleen of tg650
and C57BL/6 mice
Found at: doi:10.1371/journal.pone.0001419.s001 (0.27 MB
PDF)
Figure S2 Immunofluorescent labeling of frozen coronal
sections of brains from mice infected with late or early mouse
brain or non-TSE material
Found at: doi:10.1371/journal.pone.0001419.s002 (6.25 MB
PDF)
Figure S3 Periodic acid-Schiff and thioflavin-S staining of fixed
coronal brain sections of mice infected with late brain
Found at: doi:10.1371/journal.pone.0001419.s003 (7.95 MB
PDF)
Figure S4 Analysis of a mouse infected with vCJD case no. 4
and showing a mixed PrPres profile
Found at: doi:10.1371/journal.pone.0001419.s004 (2.63 MB
PDF)
Figure S5 End point titration of sCJD infectivity in tg650 mice
Found at: doi:10.1371/journal.pone.0001419.s005 (0.27 MB
PDF)
Table S1 Differential distribution of PrPres in the brains of
tg650 mice infected with early or late brain passage
Found at: doi:10.1371/journal.pone.0001419.s006 (0.05 MB
DOC)
Text S1 Development of the human PrP transgenic mice (tg650
line)
Found at: doi:10.1371/journal.pone.0001419.s007 (0.03 MB
DOC)
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